Identification of the Regulatory Targets of miR-3687 and miR-4417 in Prostate Cancer Cells Using a Proteomics

Simone Venz1, Heike Junker1, Erik Ultsch1

  • 1Department of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, 17475 Greifswald, Germany.

Insights

Two microRNAs, miR-3687 and miR-4417, are upregulated in castration-resistant prostate cancer (CRPC). These microRNAs (miRNAs) regulate key processes like metabolism and inflammation, potentially promoting CRPC progression by affecting tumor protein D52 isoform 1.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Proteomics

Background:

  • MicroRNAs (miRNAs) are crucial regulators of cellular processes, with deregulated expression observed in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC).
  • The specific roles and regulatory functions of many dysregulated miRNAs in cancer development remain largely unelucidated.

Purpose of the Study:

  • To investigate the functional roles and regulatory activities of hsa-miR-3687-3p (miR-3687) and hsa-miR-4417-3p (miR-4417) in CRPC.
  • To identify protein targets and cellular pathways influenced by these upregulated miRNAs in CRPC.

Main Methods:

  • Overexpression of miR-3687 and miR-4417 in PCa and CRPC cell lines.
  • Proteomic analysis using 2D gel electrophoresis, Maldi-MS/MS, and ESI-MS/MS.
  • Validation of protein expression changes via Western blotting.
  • Bioinformatic analysis including Gene Ontology and pathway analysis.

Main Results:

  • miR-3687 and miR-4417 are involved in diverse regulatory mechanisms supporting the CRPC phenotype, including metabolism and inflammation.
  • Both miRNAs are associated with extracellular vesicles, suggesting a secretory role.
  • Tumor protein D52 isoform 1 (TD52-IF1), a regulator of neuroendocrine trans-differentiation, was significantly deregulated by both miRNAs in androgen-insensitive cells.

Conclusions:

  • miR-3687 and miR-4417 play a significant role in supporting the CRPC phenotype.
  • These miRNAs may promote CRPC progression by modulating TD52-IF1 expression, particularly after the development of androgen resistance.